NASDAQ:SPRB Spruce Biosciences Q4 2024 Earnings Results & Report $46.20 -0.47 (-1.01%) Closing price 04:00 PM EasternExtended Trading$46.33 +0.13 (+0.28%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Spruce Biosciences missed analyst earnings expectations but beat on revenue in its Q4 2024 results, released April 15, 2025. The company reported EPS of -$42.75 versus the -$15.00 consensus estimate, while revenue of $550 thousand topped the $500 thousand estimate by $50.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2024Report DateApril 15, 2025TimeBefore Market OpensConference Call DateApril 14, 2025Conference Call6:00 PM ET Spruce Biosciences EPS ResultsActual EPS-$42.75Consensus EPS -$15.00Beat/MissMissed by -$27.75One Year Ago EPSN/AEPS Beat Rate3 of last 8 quartersSpruce Biosciences Revenue ResultsActual Revenue$550 thousandExpected Revenue$500 thousandBeat/MissBeat by +$50.00 thousandYoY Revenue GrowthN/AConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Spruce Biosciences Q4 2024 Earnings FAQ Did Spruce Biosciences beat earnings estimates for Q4 2024? Spruce Biosciences (NASDAQ:SPRB) reported earnings of -$42.75 per share for Q4 2024, missing the consensus estimate of -$15.00. The report was announced on Tuesday, April 15, 2025. What was Spruce Biosciences' revenue for Q4 2024? Spruce Biosciences reported revenue of $550 thousand for Q4 2024, against a consensus estimate of $500 thousand. Spruce Biosciences Earnings HeadlinesSpruce Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 10 at 11:00 PM | marketscreener.comMSpruce Biosciences Faces Funding Risk as Uncertainty Looms Over TA-ERT FDA Priority Review Voucher and Sale ProspectsNovember 10 at 1:11 AM | tipranks.comI'm handing you this one freeElon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.November 11 at 1:00 AM | Behind the Markets (Ad)Spruce Biosciences Separates CAH Program Into New Company Adrenyx BiosciencesNovember 9 at 3:04 PM | rttnews.comSpruce Biosciences establishes Adrenyx subsidiary to develop CAH treatment CRHX-101November 9 at 3:04 PM | msn.comComparing Spruce Biosciences (SPRB) and Its RivalsNovember 5, 2026 | americanbankingnews.comSee More Spruce Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Spruce Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spruce Biosciences and other key companies, straight to your email. Email Address About Spruce BiosciencesSpruce Biosciences (NASDAQ:SPRB) is a clinical-stage biopharmaceutical company focused on developing medicines for rare endocrine disorders. The company’s research is centered on conditions in which abnormal hormone production or regulation creates significant health risks and limited treatment options. Its lead investigational product is tildacerfont, an oral, selective corticotropin-releasing factor type 1 receptor antagonist. Spruce has studied tildacerfont as a potential treatment for congenital adrenal hyperplasia, a rare genetic disorder affecting the adrenal glands, and has evaluated its ability to reduce hormone imbalances associated with the disease. Tildacerfont is investigational and has not been approved for commercial use. Spruce Biosciences was founded in 2014 and is headquartered in San Francisco, California. The company’s development activities have included clinical research conducted in the United States and other regions. As a development-stage biotechnology company, Spruce has focused primarily on advancing its endocrine-disease pipeline rather than marketing an established portfolio of commercial products.View Spruce Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going AwayPowering Up the Moon: Redwire’s $40 Million NASA Award Upcoming Earnings Brookfield (11/12/2026)NU (11/12/2026)Applied Materials (11/12/2026)Cisco Systems (11/12/2026)Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
